Lasofoxifene
Top View
- Lasofoxifene Shown to Sharply Reduce Incidence of Breast Cancer
- Managing Menopausal Vasomotor and Genitourinary Symptoms After Breast Cancer
- Selective Estrogen Receptor Modulator (SERM) Lasofoxifene Forms Reactive Quinones Similar to Estradiol † † Bradley T
- Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality KAREL SMETANA, JR
- Product List
- Effects of Ospemifene on the Female Reproductive and Urinary Tracts: Translation from Preclinical Models Into Clinical Evidence
- Serms in the Prevention and Treatment of Postmenopausal Osteoporosis: an Update
- Transdermal Delivery System for Hormones and Steroids
- Effects of Lasofoxifene and Bazedoxifene on B Cell Development and Function Angelina I
- Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen
- Senshio-Epar-Public-Assessment-Report En.Pdf
- Safety of Vaginal Estrogens: a Systematic Review Supplemental
- Estrogen Receptor/ERR
- Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors
- Pharmacological Management of Osteoporosis in Postmenopausal Women: an Endocrine Society* Clinical Practice Guideline
- 203505Orig1s000
- Ospemifene for the Treatment of Menopausal Vaginal Dryness, a Symptom of the Genitourinary Syndrome of Menopause
- The Discovery and Development of Selective Estrogen Receptor Modulators (Serms) for Clinical Practice